You are here: Industry Insights > Daiichi

News List

AZ, Daiichi grab blockbuster nod for breast cancer med Enhertu fiercepharma
December 27, 2019
For metastatic breast cancer patients who try and fail on multiple treatments, finding options to manage disease is a difficult proposition.
Daiichi Sankyo Presents Positive Results from LIXIANA Study americanpharmaceuticalreview
September 05, 2019
Daiichi Sankyo announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name LIXIANA®▼) plus a P2Y12 inhibitor...
Daiichi Sankyo Reports Positive Initial Results from Bempedoic Acid / Ezetimibe Study americanpharmaceuticalreview
September 03, 2019
Daiichi Sankyo Europe GMbH announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination (FDC) tablet study (also known as Study 058).
Daiichi Sankyo Names Chief People Officer contractpharma
August 26, 2019
Simon King will human resources across all U.S. divisions.
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering b3cnewswire
August 01, 2019
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’)announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study...
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
June 25, 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
May 20, 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
AstraZeneca and Daiichi's HER2 ADC hits goal in pivotal trial fiercepharma
May 12, 2019
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) has hit the primary endpoint in a pivotal phase 2 trial, teeing the partners up to file for FDA approval in the first half of the fiscal year.
Daiichi selects oncology candidate built on Zymeworks’ Bispecific platform biospectrumasia
April 28, 2019
One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks fiercebiotech
April 28, 2019
Daiichi Sankyo has selected the first immuno-oncology candidate under its deal with Zymeworks. The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.

Previous page 1 2 Next page